A medication used to treat a type of lung disease that results in scar tissues in the lungs.


An agent used for the treatment of idiopathic pulmonary fibrosis (IPF).


Pirfenidone is an orally active small molecule drug that may inhibit collagen synthesis, down regulate production of multiple cytokines and block fibroblast proliferation and stimulation in response to cytokines. Pirfenidone has demonstrated activity in multiple fibrotic conditions, including those of the lung, kidney and liver. It is being investigated by InterMune.



For the treatment of idiopathic pulmonary fibrosis (IPF).


Pirfenidone is a novel agent with anti-inflammatory, antioxidant, and antifibrotic properties. It may improve lung function and reduce the number of acute exacerbations in patients with idiopathic pulmonary fibrosis (IPF).

Mechanism of action

Pirfenidone is an orally active, small molecule that shows a wide range of biologic activity. In vitro evidence has shown that pirfenidone inhibits collagen synthesis, down-regulates profibrotic cytokines and decreases fibroblast proliferation. Pirfenidone leads to a reduction of TGF-beta2 mRNA leve... Read more


Rapidly absorbed following oral administration.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.


Information currently not available.

Half life

2-2.5 hours

Route of elimination

Information currently not available.


Generally well tolerated with the most frequent side effects reported being photosensitivity rash and gastrointestinal symptoms.

Adverse Effects

Effect Regions Age Groups Incidences Evidence Type


Information currently not available.

Food Interactions

Take at the same time every day.

Take with food. This may reduce the adverse effects of nausea and dizziness. Food also impacts the bioavailability of pirfenidone.